AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34102783
Drug: Oral glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucocorticoid (prednisone) one week before and three weeks after operation
Trial: 32277364
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of bentysrepinine (50-900 mg)
Trial: 32277364
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of bentysrepinine (300 mg and 600 mg)
Trial: 32277364
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of bentysrepinine (600 mg) in food-effect study
Trial: 33691268
Drug: Bra prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bra prescription (wearing a prescribed bra every day for eight weeks)
Trial: 33710261
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g Schisandra chinensis Baillon extract (SCe) daily for 12 weeks
Trial: 36307427
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide 250 mg/day
Trial: 32092321
Drug: iNO 30
RxNorm normalized name: INO
DrugBank: Inosine (DB04335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iNO 30 μg/kg ideal body weight/h
Trial: 33065955
Drug: IncobotulinumtoxinA (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncobotulinumtoxinA (single-dose studies)
Trial: 33065955
Drug: IncobotulinumtoxinA (repeat-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncobotulinumtoxinA (repeat-dose studies)
Trial: 33065955
Drug: Placebo (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (single-dose studies)
Trial: 36208242
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with antivirals (including recombinant interferon alpha-2b and CHOP therapy, zidovudine combined with CHOP therapy, CHOP regimen combined with interferon and zidovudine)
Trial: 36208242
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (CHOP therapy)
Trial: 34684407
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of hydrolyzed pine nut oil (PNO-FFA)
Trial: 34684407
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 3 g hydrolyzed pine nut oil and 3 g olive oil (PNO-OO)
Trial: 34684407
Drug: Both oil
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oil treatments (PNO-FFA and PNO-OO)
Trial: 33129990
Drug: Monthly digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly digital hospitalization surveys
Trial: 34020123
Drug: Gait perturbation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gait perturbation protocol (treadmill-based, 10-week therapy)
Trial: 36317783
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of CIS43LS per kilogram
Trial: 36317783
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of CIS43LS per kilogram
Trial: 32457106
Drug: SUBA™-Itraconazole (S-ITZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUBA™-Itraconazole (S-ITZ) 2x65 mg TID for 3 days and once on day 4
Trial: 32457106
Drug: SUBA™-Itraconazole (S-ITZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUBA™-Itraconazole (S-ITZ) 2x65 mg BID for 14 days and a last dose on day 15
Trial: 32457106
Drug: Conventional Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional Itraconazole (C-ITZ) 2x100 mg TID for 3 days and once on day 4
Trial: 32457106
Drug: Conventional Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional Itraconazole (C-ITZ) 2x100 mg BID for 14 days and a last dose on day 15
Trial: 33386619
Drug: Forgiveness intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Forgiveness intervention (twice-a-week sessions for 4 months)
Trial: 33011099
Drug: Lenabasum 1
RxNorm normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenabasum 1 mg QD (Weeks 1–4)
Trial: 33011099
Drug: Lenabasum 5
RxNorm normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenabasum 5 mg QD (Weeks 1–4)
Trial: 33011099
Drug: Lenabasum 20
RxNorm normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenabasum 20 mg QD (Weeks 5–12)
Trial: 33011099
Drug: Lenabasum 20
RxNorm normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenabasum 20 mg BID (Weeks 5–12)
Trial: 33609425
Drug: 9-week nurse-led
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9-week nurse-led Internet-based cognitive behavioural therapy for insomnia (I-CBTI) with support
Trial: 33814126
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (ganirelix 0.25 mg/day)
Trial: 34489288
Drug: Indonesia Drug
RxNorm normalized name: influenza A virus A/Indonesia/05/2005 (H5N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indonesia Drug Addiction Relapse Prevention Programme (Indo-DARPP), a 12-week cognitive behavioural therapy (CBT) and motivational interviewing programme delivered via video-conferencing.
Trial: 34489288
Drug: Indonesia Drug
RxNorm normalized name: influenza A virus A/Indonesia/05/2005 (H5N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indonesia Drug Addiction Relapse Prevention Programme (Indo-DARPP)
Trial: 33176842
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg daily for 104 weeks
Trial: 32951733
Drug: Vaginal cream
RxNorm normalized name: VAGINAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal cream containing aqueous extract of Achillea millefolium
Trial: 32951733
Drug: Vaginal cream
RxNorm normalized name: VAGINAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal cream clotrimazole 1%
Trial: 33367487
Drug: Diabetes on
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes on no medication
Trial: 33367487
Drug: Diabetes on
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes on non-insulin antidiabetic drugs
Trial: 32191203
Drug: Assigned Evidence‐Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assigned Evidence‐Based Medicine (EBM) articles and Rosh Review questions
Trial: 32921117
Drug: Carbohydrate administration
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate administration 3 hours before surgery
Trial: 35177019
Drug: ACORN intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACORN intervention + Treatment as usual (TAU)
Trial: 33368937
Drug: Heat-patch treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-patch treatment
Trial: 36131308
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of local anaesthetic
Trial: 34099033
Drug: Group skills
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group skills treatment (stepped-care structured psychological group treatment)
Trial: 34403658
Drug: upadacitinib 15
RxNorm normalized name: upadacitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib 15 mg + TCS
Trial: 34403658
Drug: upadacitinib 30
RxNorm normalized name: upadacitinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib 30 mg + TCS
Trial: 32626889
Drug: Oral implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral implant restoration (experimental group)
Trial: 34638190
Drug: Ultrasound-guided bilateral
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided bilateral ESPB with 20 ml of 0.375% ropivacaine (group E)
Trial: 34251097
Drug: Phenazopyridine 200
RxNorm normalized name: phenazopyridine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenazopyridine 200 mg 3 times a day for 2 days and fosfomycin trometamol 3 g once
Trial: 34251097
Drug: Fosfomycin trometamol
RxNorm normalized name: trometamol
DrugBank: Tromethamine (DB03754)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin trometamol 3 g once and drotaverin 80 mg 3 times a day for 2 days
Trial: 33384390
Drug: Dose-escalated adaptive
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalated adaptive tumour‐focused radiotherapy (DART)
Trial: 33384390
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose adaptive tumour‐focused radiotherapy
Trial: 34915528
Drug: 16 G
RxNorm normalized name: Maltsupex, 16 g/15 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 G biopsy needle (Bard MC l616)
Trial: 34915528
Drug: 18 G
RxNorm normalized name: flotufolastat F 18 gallium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 G biopsy needle (Bard MC l820)
Trial: 33879663
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplement therapy (ONS)
Trial: 33380582
Drug: 2-week continuous
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week continuous supplementation of hydrogen-rich water (HW), 500 mL daily on weekdays (total 5 L)
Trial: 33380582
Drug: Single intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intake of hydrogen-rich water (HW), 500 mL
Trial: 34170943
Drug: Restrictive fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive fluid administration (clear fluids 0.75-1.0 times the volume of blood lost)
Trial: 34170943
Drug: Liberal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal fluid administration (clear fluids 1.5-2.0 times the volume of blood lost)
Trial: 34170943
Drug: Restrictive fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive fluid administration
Trial: 34170943
Drug: Liberal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal fluid administration
Trial: 36185576
Drug: Routine intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine intervention and chemotherapy
Trial: 34187621
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g transgenic rice
Trial: 34187621
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g transgenic rice
Trial: 32572719
Drug: OMDI 0.002%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMDI 0.002% (one drop once daily for 4 weeks)
Trial: 34997525
Drug: Didactic preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didactic preparation methods (various formats)
Trial: 33090294
Drug: Evolocumab therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab therapy
Trial: 33090294
Drug: Evolocumab therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab therapy in MI patients with uncontrolled familial hypercholesterolemia (FH)
Trial: 32633141
Drug: Drug adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug adjusted control
Trial: 35895759
Drug: 7.2% hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.2% hypertonic saline solution (HS)
Trial: 35895759
Drug: 0.9% isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% isotonic saline solution (IS)
Trial: 33342710
Drug: Rapid titration
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid titration protocols (target dose of 400 mg/day within 1 week)
Trial: 33342710
Drug: Conventional weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Conventional weekly titration protocol (target dose of 400 mg/day in three weeks)
Trial: 33461602
Drug: Inhaled magnesium
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled magnesium sulphate (5 cc of a 20% injectable vial or 2 cc of a 50% injectable vial diluted with 50 cc distilled water, nebulized via a mask) every eight hours for five days, in addition to standard treatment for COVID-19.
Trial: 33461602
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for COVID-19 only.
Trial: 36526794
Drug: Ketorolac (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (0.5 mg/kg)
Trial: 32393370
Drug: Paracetamol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (10 mg/kg)
Trial: 36322461
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (sterile saline at room temperature)
Trial: 32940751
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg intravenous methylprednisolone (study group)
Trial: 32940751
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution as placebo (control group)
Trial: 32858399
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (4 g heptahydrate, infused over 30 min)
Trial: 32698894
Drug: Dental Health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental Health Component (DHC) of the Index of Orthodontic Treatment Need (IOTN)
Trial: 32698894
Drug: Aesthetic Component
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aesthetic Component (AC) of the Index of Orthodontic Treatment Need (IOTN)
Trial: 33513879
Drug: B12 supplementation
RxNorm normalized name: Coenzyme B12
DrugBank: Cobamamide (DB11191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B12 supplementation (methylcobalamin) 1000 μg/day for one year
Trial: 35836102
Drug: peg‐IFN‐α‐2b combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peg‐IFN‐α‐2b combined with TDF, GM‐CSF, and hepatitis B vaccine
Trial: 34565664
Drug: Multisite stereotactic
RxNorm normalized name: polysaccharide iron complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisite stereotactic radiation therapy (SBRT) alone
Trial: 33492696
Drug: Sham block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham block (placebo injection)
Trial: 34403081
Drug: 5-hydroxytryptophan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hydroxytryptophan (50 mg daily)
Trial: 35050954
Drug: Drama therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drama therapy for 8 weeks
Trial: 35050954
Drug: Drama therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drama therapy for 12 weeks
Trial: 36573450
Drug: Cilofexor (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilofexor (10 to 300 mg fasting or fed, 15 and 50 mg twice-daily fed)
Trial: 36573450
Drug: Cilofexor (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilofexor (doses >30 mg)
Trial: 33172506
Drug: OMNI (animal-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMNI (animal-derived protein diet; n=9; 1.8 g/kg body mass per day)
Trial: 33172506
Drug: VEG (vegan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEG (vegan protein diet; n=10; mycoprotein providing 57% of daily protein intake; 1.8 g/kg body mass per day)
Trial: 32439253
Drug: TelePR programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TelePR programme (3 weekly training sessions, performance data sent through an app)
Trial: 32161055
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy with ambrisentan plus tadalafil (COMB)
Trial: 32161055
Drug: Monotherapy of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy of either ambrisentan or tadalafil (MONO)
Trial: 36123717
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy with patient’s musical preference at 60 dB
Trial: 33516014
Drug: Dried citrus
RxNorm normalized name: peptone,dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried citrus pulp (DCP) at 150 g/kg
Trial: 33516014
Drug: Grape pomace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape pomace (DGP) at 150 g/kg
Trial: 36555933
Drug: Rituximab 500
RxNorm normalized name: riTUXimab 500 MG in 50 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 500 mg
Trial: 36555933
Drug: Rituximab 1000
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 1000 mg
Trial: 34472200
Drug: 5‐mg flunarizine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐mg flunarizine hydrochloride capsules (test)
Trial: 34472200
Drug: 5‐mg flunarizine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐mg flunarizine hydrochloride capsules (test) with high-fat meals
Trial: 34472200
Drug: 5‐mg flunarizine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐mg flunarizine hydrochloride capsules (reference)
Trial: 36097005
Drug: Urate-lowering therapies
RxNorm normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Urate-lowering therapies (ULT) - allopurinol and febuxostat, treated during at least 75% of the study period (PT ≥ 75; n=51)
Trial: 36097005
Drug: Urate-lowering therapies
RxNorm normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Urate-lowering therapies (ULT) - treated less than 75% of the study period (PT < 75; n=31)
Trial: 33583034
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of dexamethasone (12 mg)
Trial: 33583034
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose of dexamethasone (6 mg)
Trial: 35899336
Drug: General anesthesia+ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: General anesthesia+ibuprofen suppository
Trial: 35899336
Drug: Three-drug combination
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug combination (general anesthesia + lidocaine + ibuprofen suppository)
Trial: 32565008
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day methylphenidate
Trial: 35047059
Drug: Autoimmune cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autoimmune cell therapy
Trial: 35965423
Drug: Goal-directed fluid
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed fluid therapy (GDFT) guided by a hemodynamic monitoring system
Trial: 35965423
Drug: Standard fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fluid therapy based on mean arterial pressure and diuresis
Trial: 35677096
Drug: Routine drugs
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine drugs combined with cardiac rehabilitation for 6 months
Trial: 35659704
Drug: High-dose IFNα
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IFNα (HDI)
Trial: 34391270
Drug: Sling-based manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sling-based manual therapy applied to the cervicothoracic junction (C7-T3) and upper cervical spine (C0-C1).
Trial: 32487236
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg) administered 3 times/week for 3 or 4 weeks
Trial: 32487236
Drug: Ketamine maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine maintenance (weekly infusions for 1 month, then bi-weekly for 2 months, and finally monthly for 3 months)
Trial: 35931989
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg dexmedetomidine as a perineural adjuvant
Trial: 35931989
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (20 mL 0.5% ropivacaine without dexmedetomidine)
Trial: 35931989
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg dexmedetomidine
Trial: 34808751
Drug: Bulleyaconitine A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bulleyaconitine A tablets combined with gabapentin
Trial: 34808751
Drug: Bulleyaconitine A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bulleyaconitine A tablets